4.3 Article

Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling

Journal

ONCOTARGET
Volume 7, Issue 10, Pages 10773-10787

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7387

Keywords

metformin; endothelial dysfunction; oxLDL; SIRT1; Gerotarget

Funding

  1. Ministry of Science and Technology [MOST-103-2320-B-006-050]
  2. National Cheng Kung University [NSC 100-2314-B-039-017-MY3, MOST 103-2320-B-006-050, D103-35A13]
  3. [CMU103-N-14]
  4. [CMU104-N-02]

Ask authors/readers for more resources

It is suggested that oxLDL is decisive in the initiation and development of atherosclerotic injuries. The up-regulation of oxidative stress and the generation of ROS act as key modulators in developing pro-atherosclerotic and anti-atherosclerotic processes in the human endothelial wall. In this present study, we confirmed that metformin enhanced SIRT1 and AMPK expression in human umbilical vein endothelial cells (HUVECs). Metformin also inhibited oxLDL-increased LOX-1 expression and oxLDL-collapsed AKT/eNOS levels. However, silencing SIRT1 and AMPK diminished the protective function of metformin against oxidative injuries. These results provide a new insight regarding the possible molecular mechanisms of metformin.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available